I primi 10 login.wordpress.org competitors

umbraco.com

Umbraco is the leading open-source ASP.NET Core CMS | More than 700,000 websites worldwide are powered by our flexible and editor-friendly CMS

themeisle.com

Enter your search Add one or several keywords that will help generate your domain list. It can be any mix of letters or an actual word. Get creative! Pick a blog domain Choose from the various blog names generated using various methods, some are random, some handpicked. Register new blog name Click on View Details… Read More »Blog Name Generator

showit.com

Learn how to make money from a website through products, affiliate marketing, or memberships. Real examples and tools included

weblium.com

With step-by-step instructions, customers will appreciate the posts and sales will be effective. Everyone can run Instagram for business!

durable.co

Sign up for your Durable account to access your business tools and manage your online presence.

website.com

Create a professional website for free with the Website.com website builder. Domain names, web hosting, website templates, and ecommerce solutions included.

refine.dev

We will be building a Complete React CRUD application using Refine and Airtable, a famous backend service to illustrate how you can power your applications with refine.

guidedtrack.com

GuidedTrack: Professional, custom software for anyone with an idea

cookieyes.com

CookieYes is a cookie consent solution that helps your website achieve GDPR and CCPA compliance easily. Create a lifetime free account!

scienceopen.com

Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. Methods In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. Results A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. Conclusions A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 mont